RGMb promoted CRC via the Erk1/2-BMP4-Smad1/5/8 pathways and induced oxaliplatin resistance by inhibiting JNK and p38 MAPK activation (Shi et al., 2015, 2016). The gene discussed is MAPK3; the disease is colorectal carcinoma.